Breaking News

BioArctic, Eisai Initiate Research Alliance

To further study the unique profile of the investigational drug candidate BAN240 in Alzheimer's disease

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioArctic AB has initiated a research collaboration with Eisai to further study the unique profile of the investigational drug candidate BAN2401.    The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401. This new research collaboration is intended to further characterize the unique binding profile of BAN2401.    “We welcome the opportunity to join forces with Eisai in this initiative to generate additional knowledge...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters